4,215 Shares in AstraZeneca Plc $AZN Bought by Oakworth Capital Inc.

Oakworth Capital Inc. bought a new stake in AstraZeneca Plc (NYSE:AZN) during the 3rd quarter, Holdings Channel reports. The firm bought 4,215 shares of the company’s stock, valued at approximately $681,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Mascoma Wealth Management LLC acquired a new position in shares of AstraZeneca in the first quarter valued at approximately $26,000. Roxbury Financial LLC acquired a new stake in shares of AstraZeneca during the second quarter worth $29,000. Resources Management Corp CT ADV acquired a new stake in shares of AstraZeneca during the first quarter worth $35,000. Allied Private Wealth LLC acquired a new stake in shares of AstraZeneca during the second quarter worth $35,000. Finally, GK Wealth Management LLC purchased a new position in AstraZeneca in the 3rd quarter valued at $31,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HSBC lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a research report on Tuesday, October 13th. Bank of America reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, July 1st. Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Finally, The Goldman Sachs Group restated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, July 1st. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Stock Performance

Shares of AZN opened at $170.04 on Wednesday. The company has a market capitalization of $263.71 billion, a PE ratio of 25.42 and a beta of 0.27. The stock has a fifty day moving average of $163.68 and a two-hundred day moving average of $180.39. AstraZeneca Plc has a fifty-two week low of $153.41 and a fifty-two week high of $212.71.

AstraZeneca (NYSE:AZN) last released its earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.17 earnings per share. As a group, equities research analysts forecast that AstraZeneca Plc will post 10.23 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.